Solna, Sweden, March 17h, 2026. One-carbon Therapeutics, a clinical-stage oncology company pioneering first-in-class targeted therapies based on deep understanding into cancer biology, today announced a strategic collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine. The collaboration will leverage Tempus’ proprietary, de-identified multimodal database and bioinformatics expertise to advance molecular insights supporting the clinical development of TH9619.
Through this collaboration, One-carbon Therapeutics will utilize Tempus’ analytical services to characterize the expression landscape across prioritized solid tumor indications. By integrating RNA sequencing data with clinical variables, the teams aim to uncover deep molecular insights that will inform the development of TH9619.
“Understanding the molecular dynamics of one-carbon metabolism across tumor types and treatment settings is fundamental to advancing TH9619 with precision,” said Ana Slipicevic, Chief Executive Officer at One-carbon Therapeutics. “Tempus’ depth of molecular data and analytical rigor enables us to generate statistically robust evidence that can potentially guide clinical decision making and optimize development.”
“At Tempus, our goal is to accelerate progress in oncology by translating complex molecular insights into meaningful therapeutic advances,” said Ezra Cohen, MD, Chief Medical Officer, Oncology, at Tempus. “Through comprehensive analysis of our multimodal dataset, we are supporting One-carbon Therapeutics in characterizing the metabolic signatures across diverse tumor types. These insights are essential to informing research strategies and advancing the development of next-generation targeted cancer therapies.”
By deepening the understanding of the biological mechanisms and genetic profiles associated with one-carbon metabolism across tumor types, the collaboration will strengthen the precision-driven clinical strategy for TH9619. Building on a deep understanding of how cancer cells depend on this pathway, these analyses may help identify patient populations most likely to benefit from treatment. This approach has the potential to enhance development efficiency, reduce uncertainty and ultimately help ensure that innovative targeted therapies reach the patients who need them most.
About One-carbon Therapeutics
One-carbon Therapeutics AB is a clinical-stage precision oncology company pioneering novel cancer therapies built on a deep understanding of cancer biology. Its lead program, TH9619 is a first-in-class, potent small molecule inhibitor of MTHFD1 and MTHFD2, overexpressed enzymes in cancer cells. This inhibition induces toxic folate trapping, starving tumors of the critical DNA building block thymidine, leading to DNA damage and causing cancer cell death. By combining strong mechanistic insight with rigorous clinical development, One-carbon Therapeutics aims to advance potent anti-tumor activity while maintaining improved tolerability for patients with solid tumors.
The company is headquartered in Sweden and is committed to translating cutting-edge science into transformative clinical impact for subjects worldwide.
For more information, please visit https://one-carbon.com/
About ODIN Phase 1/2 Clinical Study
This is a first-in-human, multicenter, open label, dose escalation and expansion study, aiming at evaluating safety, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of TH9619 as monotherapy in subjects with advanced refractory solid tumors, including colorectal cancer, non-small cell lung cancer, head & neck squamous cell carcinoma, gastric cancer or gastroesophageal junction cancer. The trial is currently being conducted across leading academic and clinical research centers in the United Kingdom, France and Spain, with expansion planned across additional European sites in the coming months.
Clinicaltrials.gov NCT07151040; EudraCT No. 2024-519639-40-00
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding expected outcomes and benefits of Tempus’ collaboration with One-carbon Therapeutics. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on February 24, 2026, as well as in other filings
Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
